Trevi Therapeutics, Inc.

TRVI

US89532M1018

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
2.9 ^USD	+1.75%		+8.61%	+116.42%

07-01	Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Microcap Growth Index	CI
07-01	Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000 Growth Index	CI

Trevi Therapeutics, Inc. Closes $15 Million Debt Facility Provided by Solar Capital and Square 1 Bank

January 08, 2015 at 02:00 pm

Trevi Therapeutics, Inc. announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender.

Latest news about Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Microcap Growth Index	06-30	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000 Growth Index	06-30	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000E Growth Index	06-30	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2000 Growth Index	06-30	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 2500 Growth Index	06-30	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Small Cap Comp Growth Index	06-30	CI
Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024	03-20
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20	CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis	12-05	CI
Transcript : Trevi Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough	11-02	CI
Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis	13/10/23	CI
Transcript : Trevi Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	10/08/23
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Trevi Therapeutics Files $200 Million Mixed Shelf	30/06/23	MT
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Small Cap Comp Value Index	23/06/23	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000 Index	23/06/23	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell 3000E Growth Index	23/06/23	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000E Index	23/06/23	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell Small Cap Completeness Index	23/06/23	CI
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) added to Russell 3000 Value Index	23/06/23	CI

Chart Trevi Therapeutics, Inc.

Duration

Period

More charts

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.

Sector

Biotechnology & Medical Research

Calendar

17/07/2024 - London International Cough Symposium

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.85 USD

Average target price

7.4 USD

Spread / Average Target

+159.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TREVI THERAPEUTICS, INC.	+116.42%	201M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs